Key facts
- Circular Genomics’s last known valuation is $35.0M (Dec 2025).
- It has raised $19.8M; the latest was Early Stage VC ($15.0M) in Dec 2025.
- Notable investors include Endeavor Greece, Alzheimers Drug Discovery Foundation, Comcast, Cottonwood Technology Fund, Diagnostics Accelerator — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Circular Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Circular Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Circular Genomics
Developer of RNA-based diagnostic assay designed for the treatment of depressive disorders. The company's circular diagnostics allows for an evidence-based approach to the treatment of psychiatric disorders and significantly reduces the amount of time necessary to achieve a therapeutic response in an individual patient, enabling physicians to diagnose and treat psychiatric and neurological diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2021
- Employees
- 19
- Website
- circulargenomics.com/
- Ownership
- Privately Held (backing)
Circular Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Circular Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Circular Genomics in its N-PORT filings yet. We sweep new filings monthly.